FORMULATION DEVELOPMENT – In Vitro Diffusion Studies in Transdermal Research: A Synthetic Membrane Model in Place of Human Skin
Vivek Joshi, PhD, David Brewster, and Peter Colonero present data on the applicability of a synthetic membrane (Strat-MTM) for in vitro transdermal diffusion studies in place of human or animal skin as a model.
Suniket Fulzele, PhD; Derek Moe, PhD; and Ehab Hamed, PhD; review the lyophilized wafer technology, specifically Lyoc, that offered the world’s first ODT, ODA Lyoc (sodium saccharinate and flamenol) in 1968.
Unilife CEO, Alan Shortall discusses his company’s unique business model , transformational approach to the market, and his thoughts on how to move forward.
BIOAVAILABILITY ENHANCEMENT – A Novel Spray-Drying Technology to Improve the Bioavailability of Biopharmaceutical Classification System Class II Molecules
David Shi, PhD; Andrew Loxley, PhD; Robert W. Lee, PhD; and David Fairhurst, PhD; briefly discuss a proven and scalable solid dispersion approach based on spray-drying that is suitable for BCS Class II APIs and NCEs.
EXECUTIVE INTERVIEW – NanoSmart Pharmaceuticals: Patented Delivery Platform Using Human Autoimmune Antibodies to Target Cancers & Other Debilitating Diseases
Dr. James Smith, President of NanoSmart Pharmaceuticals, discusses his company’s innovative approach to drug delivery using immunoliposomes and their unique targeting ability.
FORMULATION DEVELOPMENT – Oral Administration of an Insulin-Soybean Suspension in Streptozocin Rats: Effect of Aqueous Soybean Extract Vehicle
Antoine Al-Achi, PhD; Brijesh Patel, MS; and Sejal Patel, MS; investigate in this study the hypoglycemic activity of an insulin suspension given orally in a vehicle of soybean extract to streptozocin diabetic rats.
EXCLUSIVE ONLINE CONTENT
A pioneer in biotechnological medicines in Brazil, BIOMM is launching Nemera’s Advapen under the trade name Lifepen® for the administration of….
Vectura Group plc recently announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide preclinical development services for….
Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs)…..
In direct response to the rapid growth of the recently launched Human Factors + (HF+) program, Noble, an Aptar Pharma company, recently announced the….
EXECUTIVE INTERVIEW – Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure
Eric M. Ostertag, MD, PhD, Chief Executive Officer of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.